• Pawar Pooja S
• Dr.Kalkotwar Ramesh. S
• Mahanubhav Pooja. T

A systematic study led to SBE-β-CD (Captisol), a polyanionic variably substituted sulfobutyl ether of β-CD, SBE-β-CD have undergone extensive safety studies and are currently used in six products approved by the Food and Drug Administration (four for Captisol and two for HP-β-CD). In many medical and preclinical trials, they are also in use. This article will concentrate on recent SBE-β-CD patents and the issues that led to product development, their safety, applications, and in particular their ability to improve drug delivery. SBE-β-CD interacts very well with neutral drugs to facilitate solubility and chemical stability and interacts particularly well with cationic drugs due to its polyanionic combinations of SBE-β-CD and various drugs have been used to dissociate rapidly after injection of parenteral drugs, to have no tissue-irritating impact after intramuscular dosing and to result in the superior oral bioavailability of badly water-soluble medications. The bioavailability enhancement and the solubility of some SBE-β-CD drugs were studied..

Captisol, sulfobutyl,

"A Brief Review on Captisol", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.7, Issue 11, page no.1036-1049, November-2020, Available :http://www.jetir.org/papers/JETIR2011280.pdf

"A Brief Review on Captisol", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.7, Issue 11, page no. pp1036-1049, November-2020, Available at : http://www.jetir.org/papers/JETIR2011280.pdf